Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.

Levi, Charlène; Frémeaux-Bacchi, Véronique; Zuber, Julien; Rabant, Marion; Devriese, Magali; Snanoudj, Renaud; Scemla, Anne; Amrouche, Lucile; Mejean, Arnaud; Legendre, Christophe; Sberro-Soussan, Rebecca.
Transplantation; 101(12): 2924-2930, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-28858176